{"id":"NCT02279173","sponsor":"Amgen","briefTitle":"Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)","officialTitle":"A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-10","primaryCompletion":"2018-08-30","completion":"2019-08-08","firstPosted":"2014-10-30","resultsPosted":"2019-08-28","lastUpdate":"2022-06-23"},"enrollment":203,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Immune Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"Romiplostim","otherNames":["Nplate"]}],"arms":[{"label":"Romiplostim","type":"EXPERIMENTAL"}],"summary":"This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10\\^9/L in the absence of ITP rescue medications for the past 4 weeks.","primaryOutcome":{"measure":"Percentage of Time With a Platelet Response During the First 6 Months of Treatment","timeFrame":"Week 2 to Month 6, platelet response was assessed every week.","effectByArm":[{"arm":"Romiplostim","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":25},"locations":{"siteCount":78,"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","France","Hungary","Israel","Mexico","Poland","Russia","South Africa","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["32902132","35413092"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":203},"commonTop":["Headache","Epistaxis","Nasopharyngitis","Pyrexia","Cough"]}}